AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26137564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose patritumab
Number of subjects: 215
Study 26137564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose patritumab
Number of subjects: 215
Study 26137564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 23314982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU daily for 5 days)
Number of subjects: 0
Study 23314982 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimal medical therapy without vitamin D supplementation)
Number of subjects: 0
Study 23314982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 21606648 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3,600 mg/day
Number of subjects: 22
Study 21606648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18642635 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 22
Study 18642635 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention (control treatment)
Number of subjects: 22
Study 21411701 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α/β receptor expression
Number of subjects: 40
Study 27945235 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-ACC-RCT with 5-FU (600mg/m²/d) and carboplatin (70mg/m²/d) on days 1-5 and 29-33
Number of subjects: 263
Study 27945235 — intervention group
Group type: COMPARATOR
Intervention: HF-ACC RT alone
Number of subjects: 263
Study 27945235 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-ACC-RCT
Number of subjects: 263
Study 27945235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapeutical Hb levels >13.5 g/dl
Number of subjects: 263
Study 27945235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapeutical Hb levels <12.7 g/dl and >14.75 g/dl
Number of subjects: 263
Study 27945235 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT and RT
Number of subjects: 263
Study 11814373 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation (Group A, n = 70) - 350 mg ferrous sulfate and 1.5 mg folic acid once daily for 90 to 100 days
Number of subjects: 209
Study 11814373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation (Group B, n = 67) - same dosage as Group A but administered once a week for 14 weeks
Number of subjects: 209
Study 11814373 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n = 72) - no supplementation
Number of subjects: 209
Study 9588656 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3-4 times a week at 70% maximum capacity for 6 months)
Number of subjects: 229
Study 8047802 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone plus magnesium hydroxide and aluminum hydroxide
Number of subjects: 80
Study 8047802 — intervention group
Group type: COMPARATOR
Intervention: Domperidone plus alginate
Number of subjects: 80
Study 8047802 — intervention group
Group type: COMPARATOR
Intervention: Domperidone alone
Number of subjects: 80
Study 8047802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2903057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide, methotrexate and 5-fluorouracil
Number of subjects: 1629
Study 2903057 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1629
Study 807223 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 603
Study 807223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603
Study 29536984 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat group (WG)
Number of subjects: 80
Study 29536984 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (TG)
Number of subjects: 80
Study 27666179 — intervention group
Group type: EXPERIMENTAL
Intervention: US participants (n=3,706)
Number of subjects: 5451
Study 27666179 — intervention group
Group type: COMPARATOR
Intervention: Non-US participants (n=1,745)
Number of subjects: 5451
Study 27666179 — intervention group
Group type: EXPERIMENTAL
Intervention: US participants hospitalized with unstable angina
Number of subjects: 5451
Study 27666179 — intervention group
Group type: COMPARATOR
Intervention: Non-US participants hospitalized with unstable angina
Number of subjects: 5451
Study 27666179 — intervention group
Group type: EXPERIMENTAL
Intervention: US geographic disposition
Number of subjects: 5451
Study 24931587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg twice daily)
Number of subjects: 20
Study 24931587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22466027 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-TENS (100 Hz)
Number of subjects: 75
Study 22466027 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-TENS (4 Hz)
Number of subjects: 75
Study 22466027 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 75
Study 19195824 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-conventional polyethylene (CP)
Number of subjects: 55
Study 19195824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic-on-ceramic (CC)
Number of subjects: 55
Study 18308996 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate 4%
Number of subjects: 61
Study 18308996 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 61
Study 15266308 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine (group I, n=14)
Number of subjects: 29
Study 15266308 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II, n=15)
Number of subjects: 29
Study 11880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 30
Study 11880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (CC)
Number of subjects: 30
Study 11880817 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (E)
Number of subjects: 30
Study 10084558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose short synacthen test (LDSST) - 1 microg tetracosactrin, ACTH-(1-24)
Number of subjects: 64
Study 10084558 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose short synacthen test (SST) - 250 microg tetracosactrin, ACTH-(1-24)
Number of subjects: 64
Study 10084558 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 64
Study 7752296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine only
Number of subjects: 152
Study 7752296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and naltrexone
Number of subjects: 152
Study 7752296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and naloxone
Number of subjects: 152
Study 7752296 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 152
Study 2321994 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% tretinoin solution applied once a day under tape occlusion or twice a day unoccluded for 4 months
Number of subjects: 21
Study 2321994 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing 50% alcohol
Number of subjects: 21
Study 379722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (N = 14)
Number of subjects: 29
Study 379722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 15)
Number of subjects: 29
Study 31381249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy group (n = 21)
Number of subjects: 398
Study 31381249 — intervention group
Group type: COMPARATOR
Intervention: Non-cystectomy group (n = 336)
Number of subjects: 398
Study 31474178 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance Training (VRT)
Number of subjects: 36
Study 31474178 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Constant External Resistance (DCER)
Number of subjects: 36
Study 31474178 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 29252022 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey administration (e-mail distribution)
Number of subjects: 132
Study 29252022 — intervention group
Group type: COMPARATOR
Intervention: In-clinic survey administration
Number of subjects: 132
Study 29252022 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey administration
Number of subjects: 132
Study 26156911 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-Fentanyl (MF)
Number of subjects: 64
Study 26156911 — intervention group
Group type: COMPARATOR
Intervention: Propofol-Remifentanil (PR)
Number of subjects: 64
Study 23281420 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg intra-articular morphine
Number of subjects: 40
Study 23281420 — intervention group
Group type: COMPARATOR
Intervention: 5 mg intra-articular morphine
Number of subjects: 40
Study 23281420 — intervention group
Group type: COMPARATOR
Intervention: 10 mg intra-articular morphine
Number of subjects: 40
Study 23281420 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control group)
Number of subjects: 40
Study 23281420 — intervention group
Group type: COMPARATOR
Intervention: 0.5% intra-articular bupivacaine
Number of subjects: 40
Study 20937715 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation
Number of subjects: 0
Study 20937715 — intervention group
Group type: COMPARATOR
Intervention: Platform rotation (20 deg s−1)
Number of subjects: 0
Study 19337769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar cane policosanols (10 mg/day)
Number of subjects: 21
Study 19337769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (incorporated in margarine)
Number of subjects: 21
Study 17262862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chito‐Seal pad
Number of subjects: 184
Study 17262862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clo‐Sur PAD
Number of subjects: 184
Study 17262862 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (ACT < 250)
Number of subjects: 184
Study 17262862 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (ACT < 170)
Number of subjects: 184
Study 12913699 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormone therapy (NHT) with 100 mg cyproterone acetate 3 times daily before surgery
Number of subjects: 213
Study 12913699 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 213
Study 12913699 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormone therapy (NHT)
Number of subjects: 213
Study 11064528 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert judgment in routine practice
Number of subjects: 474
Study 11064528 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 474
Study 11064528 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' belief in effective treatments and perceived ability to cope
Number of subjects: 474
Study 8829026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel (2.5% w/w)
Number of subjects: 1575
Study 8829026 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam gel (0.5% w/w)
Number of subjects: 1575
Study 8829026 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel (1% w/w)
Number of subjects: 1575
Study 1483069 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled platelet-activating factor (200 micrograms)
Number of subjects: 6
Study 1483069 — intervention group
Group type: COMPARATOR
Intervention: Methacholine (control)
Number of subjects: 6
Study 3912961 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 23
Study 3912961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS)
Number of subjects: 23
Study 3912961 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 23
Study 3912961 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for TENS
Number of subjects: 23
Study 30959227 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels in females
Number of subjects: 220
Study 30959227 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels in males
Number of subjects: 220
Study 30959227 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP reduction from baseline to week-8
Number of subjects: 220
Study 30959227 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in HAMD-17 and CRP
Number of subjects: 220
Study 29107324 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon surgery (n=298)
Number of subjects: 596
Study 29107324 — intervention group
Group type: COMPARATOR
Intervention: Morning surgery (n=298)
Number of subjects: 596
Study 29107324 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon surgery (n=44)
Number of subjects: 596
Study 29107324 — intervention group
Group type: COMPARATOR
Intervention: Morning surgery (n=44)
Number of subjects: 596
Study 26015451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (four times daily at 60% to 70% of VO2max for four weeks)
Number of subjects: 120
Study 26015451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (four weeks)
Number of subjects: 120
Study 26015451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 120
Study 25346155 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR (combined prolonged-release oxycodone and naloxone)
Number of subjects: 474
Study 25346155 — intervention group
Group type: COMPARATOR
Intervention: Oxy PR (oxycodone prolonged-release tablets)
Number of subjects: 474
Study 25346155 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR
Number of subjects: 474
Study 22169699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) treatment (3 weekly injections of 2 ml of 20 mg/ml HA)
Number of subjects: 30
Study 22169699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) (3 weekly injections of 1.2 ml of 0.001 mg/ml HA)
Number of subjects: 30
Study 20609251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention program
Number of subjects: 0
Study 20609251 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 18032992 — intervention group
Group type: EXPERIMENTAL
Intervention: Video counseling with immediate testing
Number of subjects: 805
Study 18032992 — intervention group
Group type: COMPARATOR
Intervention: Standard care (referral to counseling and testing the next day)
Number of subjects: 805
Study 15859371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 25
Study 15859371 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 12106842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic-derived regional deformation parameters (peak systolic strain rate and systolic strain) in TOF patients
Number of subjects: 30
Study 12106842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic-derived regional deformation parameters in TOF patients
Number of subjects: 30
Study 9704607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestration patients (hemapheresis with normovolemic hemodilution)
Number of subjects: 160
Study 9704607 — intervention group
Group type: COMPARATOR
Intervention: IAT only patients (control group)
Number of subjects: 160
Study 9704607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestration patients
Number of subjects: 160
Study 7853086 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared tympanic thermometer
Number of subjects: 34
Study 7853086 — intervention group
Group type: COMPARATOR
Intervention: Axillary thermometer
Number of subjects: 34
Study 7853086 — intervention group
Group type: COMPARATOR
Intervention: Rectal thermometer
Number of subjects: 34
Study 2697210 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone plus low‐dose cyclosporin A (CyA; median dose 109 mg/m2 per day = 3.4 mg/kg per day after 1 year)
Number of subjects: 51
Study 2697210 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone plus azathioprine (AZA)
Number of subjects: 51
Study 2697210 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone plus low‐dose cyclosporin A (CyA)
Number of subjects: 51
Study 202141 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 0
Study 202141 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 0
Study 202141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30826339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 132
Study 30826339 — intervention group
Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 132
Study 29870029 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 114
Study 29870029 — intervention group
Group type: COMPARATOR
Intervention: Non-metformin (Control)
Number of subjects: 114
Study 26936907 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 3280
Study 26936907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3280
Study 24880577 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromuscular inset of a lightweight polypropylene mesh
Number of subjects: 57
Study 24880577 — intervention group
Group type: COMPARATOR
Intervention: Dual closure of the anterior rectus fascia using Quill self‐locking technology
Number of subjects: 57
Study 22497697 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 200mg twice daily (bid)
Number of subjects: 596
Study 22497697 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 596
Study 19436015 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home-based tailored program of telephone counseling and mailed materials promoting exercise, improved diet quality, and modest weight loss.
Number of subjects: 641
Study 17846101 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Problem‐Solving Therapy in Home Care (PST‐HC)
Number of subjects: 40
Study 17846101 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 40
Study 15100513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Number of subjects: 0
Study 15100513 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the promontory
Number of subjects: 0
Study 15100513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation (subset analysis)
Number of subjects: 0
Study 11428528 — intervention group
Group type: EXPERIMENTAL
Intervention: Progress 3 aspheric multifocal IOL
Number of subjects: 40
Study 11428528 — intervention group
Group type: COMPARATOR
Intervention: Conventional monofocal IOL
Number of subjects: 40
Study 10179701 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluations in healthcare interventions
Number of subjects: 0
Study 10179701 — intervention group
Group type: EXPERIMENTAL
Intervention: Good quality clinical data
Number of subjects: 0
Study 10179701 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant costs and outcomes
Number of subjects: 0
Study 10179701 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate methods of data analysis
Number of subjects: 0
Study 10179701 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of results
Number of subjects: 0
Study 8052342 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 200 mg at bedtime
Number of subjects: 12
Study 8052342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3053562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin with clavulanic acid (Augmentin) for prophylaxis against wound infections
Number of subjects: 46
Study 3053562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 46
Study 3053562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (post-trial)
Number of subjects: 46
Study 1610673 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 0
Study 1610673 — intervention group
Group type: COMPARATOR
Intervention: Conventional long stay hospital wards
Number of subjects: 0
Study 321709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 77
Study 321709 — intervention group
Group type: COMPARATOR
Intervention: Penicillin plus Chloramphenicol
Number of subjects: 77
Study 31340042 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV high dose (5 × 10^10 viral particles)
Number of subjects: 72
Study 31340042 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd155-RSV low dose (5 × 10^9 viral particles)
Number of subjects: 72
Study 31340042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31340042 — intervention group
Group type: COMPARATOR
Intervention: Active control (Bexsero)
Number of subjects: 72
Study 27815105 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 44
Study 27815105 — intervention group
Group type: COMPARATOR
Intervention: Non-buffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 44
Study 26407616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐fascial continuous local anaesthetic wound infusion (CLAWI) with 0.2% Bupivacaine plus intravenous paracetamol and rescue intravenous morphine
Number of subjects: 60
Study 26407616 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (EPI) plus paracetamol and rescue intravenous morphine
Number of subjects: 60
Study 26407616 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine and paracetamol (standard post‐operative analgesia—SAPA)
Number of subjects: 60
Study 26407616 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAWI group
Number of subjects: 60
Study 24411121 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention
Number of subjects: 220
Study 24411121 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience intervention
Number of subjects: 220
Study 24411121 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 220
Study 22079215 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (CBT)
Number of subjects: 44
Study 22079215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44